AstriVax
Bart Geers is an experienced investment manager at KU Leuven since June 2018. Additionally, Bart serves as a board member for various companies, including Tavira Therapeutics, AstriVax, Pulsify Medical, FOx Biosystems, and Augustine Therapeutics, and holds the position of Chairman of the Board for RegMed XB Flanders VZW. Prior to these roles, Bart worked as a Senior Scientist and Valorisation Manager at Ghent University and managed the Center for Nano and Biophotonics from August 2013 to May 2018. Bart's early career includes a role as a Quality Engineer at Alcon and an academic assistant at Ghent University. Educational qualifications include a Doctor of Philosophy in Pharmacy and a Master in Pharmaceutical Sciences, both from Ghent University, complemented by a secondary education focused on Latin and Mathematics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
AstriVax
1 followers
AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.